Psoriatic Arthritis – Pipeline Review, H2 2012

Published by: Global Markets Direct

Published: Sep. 25, 2012 - 47 Pages

Table of Contents

Introduction

Global Markets Direct Report Coverage

Psoriatic Arthritis Overview

Therapeutics Development

An Overview of Pipeline Products for Psoriatic Arthritis

Psoriatic Arthritis Therapeutics under Development by Companies

Late Stage Products

Comparative Analysis

Mid Clinical Stage Products

Comparative Analysis

Early Clinical Stage Products

Comparative Analysis

Pre-Clinical Stage Products

Comparative Analysis

Psoriatic Arthritis Therapeutics – Products under Development by Companies

Companies Involved in Psoriatic Arthritis Therapeutics Development

F. Hoffmann-La Roche Ltd.

Amgen Inc.

Eli Lilly and Company

Celltrion, Inc.

Pfizer Inc.

UCB Group

Celgene Corporation

Protalix BioTherapeutics, Inc.

Alder Biopharmaceuticals Inc.

Centocor Ortho Biotech, Inc.

Psoriatic Arthritis – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Molecule Type

Psoriatic Arthritis Therapeutics – Discontinued Products

Psoriatic Arthritis Therapeutics - Dormant Products

Psoriatic Arthritis – Product Development Milestones

Featured News & Press Releases

Jul 26, 2012: Horizon Pharma Announces FDA Approval Of RAYOS Tablets For Rheumatoid Arthritis And Multiple Additional Indications

Jul 19, 2012: CHMP Adopted Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Abbott's Humira

Jul 12, 2012: Celgene's Apremilast Achieves Statistical Significance For Primary Endpoint Of First Phase III Study In Patients With Psoriatic Arthritis

Jun 21, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Enbrel

Jun 06, 2012: UCB Presents Results From RAPID-PsA Study Of Certolizumab Pegol At EULAR Annual European Congress Of Rheumatology

Jun 05, 2012: Janssen Reports Positive Data From Phase III Study Of STELARA For Treatment Of Psoriatic Arthritis At EULAR Annual Congress

Feb 16, 2012: UCB Announces Positive Top-Line Results For Cimzia In Psoriatic Arthritis

Sep 09, 2011: Janssen Biotech Receives Complete Response Letter For SIMPONI Supplemental Biologics License Application

May 25, 2011: Amgen And Pfizer Announce New Results From Multiple Studies Of ENBREL

Apr 26, 2011: NICE Recommends Golimumab For Treatment Of Psoriatic Arthritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products Under Development for Psoriatic Arthritis, H2 2012

Products under Development for Psoriatic Arthritis – Comparative Analysis, H2 2012

Number of Products under Development by Companies, H2 2012

Comparative Analysis by Late Stage Development, H2 2012

Comparative Analysis by Mid Clinical Stage Development, H2 2012

Comparative Analysis by Early Clinical Stage Development, H2 2012

Comparative Analysis by Pre-Clinical Stage Development, H2 2012

Products under Development by Companies, H2 2012

F. Hoffmann-La Roche Ltd., H2 2012

Amgen Inc., H2 2012

Eli Lilly and Company, H2 2012

Celltrion, Inc., H2 2012

Pfizer Inc., H2 2012

UCB Group, H2 2012

Celgene Corporation, H2 2012

Protalix BioTherapeutics, Inc., H2 2012

Alder Biopharmaceuticals Inc., H2 2012

Centocor Ortho Biotech, Inc., H2 2012

Assessment by Monotherapy Products, H2 2012

Assessment by Stage and Route of Administration, H2 2012

Assessment by Stage and Molecule Type, H2 2012

Psoriatic Arthritis Therapeutics – Discontinued Products

Psoriatic Arthritis Therapeutics – Dormant Products

List of Figures

Number of Products under Development for Psoriatic Arthritis, H2 2012

Products under Development for Psoriatic Arthritis – Comparative Analysis, H2 2012

Products under Development by Companies, H2 2012

Late Stage Products, H2 2012

Mid Clinical Stage Products, H2 2012

Early Clinical Stage Products, H2 2012

Pre-Clinical Stage Products, H2 2012

Assessment by Monotherapy Products, H2 2012

Assessment by Route of Administration, H2 2012

Assessment by Stage and Route of Administration, H2 2012

Assessment by Molecule Type, H2 2012

Assessment by Stage and Molecule Type, H2 2012

Abstract

• A snapshot of the global therapeutic scenario for Psoriatic Arthritis.
• A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Psoriatic Arthritis pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

• Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.